Clinical trials for Prostate cancer
145 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT05503797
#2024-513578-23-00
Locally Advanced
Metastatic
BRAF
1
2
3 or more
KRAS G12C
KRAS non G12C
NRAS
HRAS
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Nord de Marseille (Marseille Cedex 20), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest) (and 2 more...)
Fore Biotherapeutics
Phase 2
Prostate cancer
#NCT04536805
Biochemical recurrence
None
Surgery
Radiotherapy
Hormone therapy
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire Laennec (Saint-Herblain), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Institut de Cancérologie de l'Ouest
Phase 2
Prostate cancer
#NCT06004661
Metastatic Castration-resistant
PSMA PET Positive
1
Hormone therapy
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
Hôpital Louis Pradel (Bron ), CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Hôpital Cochin (Paris )
Novartis
Phase 2
Prostate cancer
#NCT03845751
Localized
None
Systemic Treatment-Naive
Institut Mutualiste Montsouris (Paris)
Institut Mutualiste Montsouris
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
#NCT03093116
#2024-512606-25-00
Metastatic
NTRK-1/2/3
1
2
3 or more
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Gustave Roussy (Villejuif), Centre Antoine Lacassagne (Nice)
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
#NCT05768139
#2023-000442-41
Cohortes monothérapie (partie 1)
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Squamous cell carcinoma
HR Positive
Locally Advanced
Metastatic
PIK3CA
1
2
3 or more
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux), IUCT Oncopôle (Toulouse)
Eli Lilly et compagnie
Phase 1 / Phase 2
Breast cancer
Prostate cancer
#NCT06253130
#2023-509230-19
Locally Advanced
Metastatic
Metastatic Castration-resistant
ATM
BRCA 1/2
CHEK 1/2
PALB2
Other mutation
1
2
3 or more
Chemotherapy
Chemotherapy
Hormone therapy
Centre François Baclesse (Caen ), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Gustave Roussy (Villejuif)
Eikon Therapeutics
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
#NCT03093116
#2024-512606-25-00
Metastatic
NTRK-1/2/3
1
2
3 or more
Targeted therapy
Systemic Treatment-Naive
Gustave Roussy (Villejuif), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers)
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
#NCT04657068
#2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Locally Advanced
Metastatic
Metastatic Castration-resistant
ATM
1
2
3 or more
Systemic Treatment-Naive
Hôpital Saint Louis AP-HP (Paris), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital de la Timone AP-HM (Marseille)
Artios Pharma Ltd
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
#NCT04657068
#2024-511534-12-00
Dose d'expansion Partie B4
Locally Advanced
Metastatic
Metastatic Castration-resistant
ATM
1
2
3 or more
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital de la Timone AP-HM (Marseille), Hôpital Saint Louis AP-HP (Paris)
Artios Pharma Ltd